Most patients with common thyroid cancer survive regardless of treatment
May 18th, 2010 - 5:11 pm ICT by ANIWashington, May 18 (ANI): People with papillary thyroid cancer that has not spread beyond the thyroid gland have positive outcomes regardless of whether they receive treatment within the first year after diagnosis, a new research has shown.
Louise Davies, of Dartmouth Medical School, Hanover, N.H. and Gilbert Welch, both also of Department of Veterans Affairs Medical Center, White River Junction, Vt., and The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, studied cancer cases and individual treatment data from National Cancer Institute registries.
They then tracked cause of death through the National Vital Statistics System.
The researchers identified 35,663 patients with papillary thyroid cancer that had not spread to the lymph nodes or other areas at diagnosis. Of these, 440 (1.2 percent) did not undergo immediate, definitive treatment. Over an average of six years of follow-up, six of these patients died of their cancer.
This was not significantly different from the rate of cancer death among the 35,223 individuals who did undergo treatment (161 over an average of 7.6 years of follow-up).
The 20-year survival rate from cancer was estimated to be 97 percent for those who did not receive treatment and 99 percent for those who did.
“These data help put management decisions about localized papillary thyroid cancer in perspective: papillary thyroid cancers of any size that are confined to the thyroid gland, have no lymph node metastases at presentation and do not show extraglandular extension [reach beyond the thyroid gland] are unlikely to result in death due to the cancer,” the authors said.
“Thus, clinicians and patients should feel comfortable considering the option to observe for a year or longer cancers that fall into this category.
“When treatment is elected, the cancers in this category can be managed with either hemithyroidectomy [removal of part of the thyroid] or total thyroidectomy [removal of the complete gland], and the prognosis will be the same,” they added.
The study has been reported in the May issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals. (ANI)
- Argentine president to undergo surgery for thyroid cancer - Dec 28, 2011
- Lymph node removal 'not always needed in early-stage breast cancer' - Feb 09, 2011
- Novel imaging technique may cut lymphedema in breast cancer patients - Dec 12, 2010
- Argentine president gets good news - no cancer - Jan 08, 2012
- Air travel safe for breast cancer survivors: Study - Aug 20, 2010
- New imaging technique may reduce lymphedema in breast cancer patients - Dec 13, 2010
- Less Invasive Breast cancer surgery gives new hope for patients - Sep 25, 2010
- Pathology tests give cancer cells a miss - Mar 02, 2011
- Ultrasound as effective as CT scans in most cases - May 12, 2011
- PET-CT scans may help predict response to head, neck cancer treatment - Nov 17, 2009
- New cancer vaccine Out - May 03, 2010
- Radiation ineffective after mastectomy, says study - Mar 07, 2010
- New technology can help identify melanoma stage with more accuracy - Feb 24, 2010
- Myths About Thyroid Disease Demystified - Jan 06, 2011
- Molecular predictor of metastatic prostate cancer identified - Feb 03, 2011
Tags: affairs medical center, cancer cases, cancer death, dartmouth medical school, definitive treatment, department of veterans affairs, lymph node metastases, management decisions, medical school hanover, national cancer institute, national vital statistics, national vital statistics system, papillary thyroid cancer, thyro, thyroid cancers, thyroid gland, veterans affairs medical, veterans affairs medical center, vital statistics system, white river junction vt